{"webUser":null}
Audioboom logo
Menu
Audioboom logo
  • Podcasts
  • Advertisers
  • Creators
  • Help & support
  • Sign up
  • Sign in
{"flashNotices":[]}
Podcasts
Advertisers
Creators
Help & support
Search podcasts
Sign up
Sign in

BIOTECH

May 14, 2014, 02:15 PM

Share
Facebook X

Dr DarrIn Disley CEO of a leading Cambridge Biotech, Horizon Discovery tells Paul Stainton, Pfizer's bid to take over #AstraZeneca is 'not in public interest'.

Share
Facebook X
Next
Peterborough Sex Grooming
Top episodes
UKIP Posters
by BBCCAMBRIDGESHIRE
U's fans stuck on the M6
by BBCCAMBRIDGESHIRE
D-Day Remembered 2
by BBCCAMBRIDGESHIRE
Related episodes
Gregory Zuckerman describes the climactic moment vaccine results arrived, with Pfizer and Moderna reporting high efficacy, while Novavax and AstraZeneca faced unique logistical and reputational challenges. 7
by The John Batchelor Show
Gregory Zuckerman examines the global race between Oxford-AstraZeneca, Pfizer-BioNTech, and J&J, emphasizing the different scientific approaches and the logistical advantages of one-shot vaccines. 6
by The John Batchelor Show
No One's Quick As Gascón
by What A Day
  •   Report this episode
  •   Download audio
For podcasters For advertisers For listeners
About us Help & feedback Service status
Blog Investors Strategic review
Terms & conditions Privacy policy Cookie policy
© 2026 Audioboom

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

Page load failed

Please check your internet connection and refresh the page. You might also try disabling any ad blockers.

You can visit our support center if you're having problems.